AMGN vs MRNA
Amgen Inc. and Moderna, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | AMGN | MRNA |
|---|---|---|
| Revenue | $36.8B | $1.9B |
| Net income | $7.7B | $-2.8B |
| Gross margin | 67.2% | 55.3% |
| Net margin | 21.0% | −145.2% |
| Return on equity | 106.1% | −28.9% |
| Diluted EPS | $14.23 | −$7.26 |
| Dividend / share | $9.66 | · |
| Payout ratio | 66.5% | · |
| Free cash flow | $8.1B | $-2.1B |
| Equity | $8.7B | $8.7B |
| Net debt / equity | 5.25× | −0.23× |
| Current ratio | 1.14× | 3.29× |
| Revenue CAGR 5y | 7.6% | 19.3% |
| Profit CAGR 5y | 1.2% | · |
AMGN bills 18.9× the revenue of MRNA, and MRNA closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | AMGN | MRNA |
|---|---|---|
| FY2025 | $36.8B | $1.9B |
| FY2024 | $33.4B | $3.2B |
| FY2023 | $28.2B | $6.8B |
| FY2022 | $26.3B | $19.3B |
| FY2021 | $26.0B | $18.5B |
| FY2020 | $25.4B | $803.0M |
| FY2019 | $23.4B | $60.0M |
| FY2018 | $23.7B | $135.1M |
| FY2017 | $22.8B | $205.8M |
| FY2016 | $23.0B | $108.4M |
Bottom line
| Fiscal year | AMGN | MRNA |
|---|---|---|
| FY2025 | $7.7B | $-2.8B |
| FY2024 | $4.1B | $-3.6B |
| FY2023 | $6.7B | $-4.7B |
| FY2022 | $6.6B | $8.4B |
| FY2021 | $5.9B | $12.2B |
| FY2020 | $7.3B | $-747.0M |
| FY2019 | $7.8B | $-514.0M |
| FY2018 | $8.4B | $-384.7M |
| FY2017 | $2.0B | $-255.9M |
| FY2016 | $7.7B | $-216.2M |
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$34,807,000,000 | AMGN |
| FY2024 | +$30,188,000,000 | AMGN |
| FY2023 | +$21,342,000,000 | AMGN |
| FY2022 | +$7,060,000,000 | AMGN |
| FY2021 | +$7,508,000,000 | AMGN |
| FY2020 | +$24,621,000,000 | AMGN |
| FY2019 | +$23,302,000,000 | AMGN |
| FY2018 | +$23,611,932,000 | AMGN |
| FY2017 | +$22,643,175,000 | AMGN |
| FY2016 | +$22,882,604,000 | AMGN |
AMGN has reported the higher revenue in every one of these 10 fiscal years. The gap has widened since the earliest year compared.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
9 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +166.1 pp | AMGN |
| FY2024 | +122.3 pp | AMGN |
| FY2023 | +92.7 pp | AMGN |
| FY2022 | −18.5 pp | MRNA |
| FY2020 | +121.6 pp | AMGN |
| FY2019 | +890.2 pp | AMGN |
| FY2018 | +320.2 pp | AMGN |
| FY2017 | +133.0 pp | AMGN |
| FY2016 | +233.1 pp | AMGN |
The higher net margin has changed hands between AMGN and MRNA over this period.
9 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MRNA's net margin has been more volatile than AMGN's over the 9 comparable fiscal years — 245.6 percentage points of standard deviation against 8.9.
9 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between AMGN and MRNA over these 9 fiscal years — AMGN led in 8 and MRNA in 1.
9 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MRNA's return on equity has been more volatile than AMGN's over the 7 comparable fiscal years — 64.6 percentage points of standard deviation against 26.6.
7 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between AMGN and MRNA over these 7 fiscal years — AMGN led in 6 and MRNA in 1.
7 of 19 comparable fiscal years — a year missing data on either side is not counted.